← Back to all trials
Recruiting
NCT07517250
A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
Conditions: Familial Mediterranean Fever, Still Disease, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still Disease
Sex: All
Ages: 1 Year – N/A
Healthy volunteers: No
Enrollment: 160
Sponsor: Novartis Pharmaceuticals
Location: Novartis Basel
Summary
This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.
Eligibility Criteria
Inclusion criteria:
* Pediatric or adult patients who were prescribed canakinumab before October 2021 and received canakinumab for at least 6 months for the treatment of FMF or Still's disease (including SJIA or AOSD).
* Have data on clinical characteristics and treatments available for at least 3 years following the initiation of canakinumab treatment.
Exclusion criteria:
• Patients Aged \
Source: ClinicalTrials.gov (NCT07517250). StuddyBuddy aggregates publicly available trial information.
